Genomtec Balance Sheet Health
Financial Health criteria checks 5/6
Genomtec has a total shareholder equity of PLN12.8M and total debt of PLN403.0K, which brings its debt-to-equity ratio to 3.2%. Its total assets and total liabilities are PLN24.9M and PLN12.1M respectively.
Key information
3.2%
Debt to equity ratio
zł403.00k
Debt
| Interest coverage ratio | n/a |
| Cash | zł14.06m |
| Equity | zł12.77m |
| Total liabilities | zł12.10m |
| Total assets | zł24.87m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 4VI's short term assets (PLN15.9M) exceed its short term liabilities (PLN7.7M).
Long Term Liabilities: 4VI's short term assets (PLN15.9M) exceed its long term liabilities (PLN4.4M).
Debt to Equity History and Analysis
Debt Level: 4VI has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 4VI's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4VI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4VI has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 26.8% each year.